Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00673673 · ClinicalTrials.gov registry record · Phase 2

FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer

A Phase 2 study of Gastric Cancer and GastroEsophageal Cancer, sponsored by Yale University.

Completed
Registry status
Phase 2
Development phase
39
Enrollment target
2
Study locations

NCT00673673: Completed Phase 2 study of Gastric Cancer and GastroEsophageal Cancer, sponsored by Yale University.

NCT00673673 is a Phase 2 study of Gastric Cancer and GastroEsophageal Cancer that has completed, run by Yale University. The registered enrollment target is 39 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00673673, a Phase 2 study of Gastric Cancer and GastroEsophageal Cancer, has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 2
Development phase
39 participants
Enrollment target
2
Study locations

Study Summary

This is a Phase II open-label study to determine the anti-tumor efficacy and tolerability of FOLFOX in combination with bevacizumab (Avastin(TM))in patients with metastatic or unresectable gastroesophageal and gastric adenocarcinoma. Our primary objective is to determine the time to progression in patients treated with FOLFOX in combination with bevacizumab.

Conditions Studied

Gastric Cancer GastroEsophageal Cancer

Interventions

  • DRUG FOLFOX
  • DRUG bevacizumab

Study Locations (2)

Connecticut

  • Medical Oncology & Hematology PC - Hamden
  • Yale University School of Medicine - New Haven

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2008-05
Est. Completion 2014-07
Phase Phase 2
Yale University

1,492 total trials

What the finished NCT00673673 record still lists

NCT00673673 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (88% lower).

The record links to 2 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 2 interventions - of which FOLFOX is the first listed.

NCT00673673 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT00673673 about?

NCT00673673 is a clinical study titled "FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer". This is a Phase II open-label study to determine the anti-tumor efficacy and tolerability of FOLFOX in combination with bevacizumab (Avastin(TM))in patients with metastatic or unresectable gastroesophageal and gastric adenocarcinoma. Our primary objective is to determine the time to progression in p...

What is the current status of trial NCT00673673?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2008-05. Estimated completion is 2014-07.

What conditions does trial NCT00673673 study?

This clinical trial studies the following conditions: Gastric Cancer, GastroEsophageal Cancer.

What interventions are being tested in trial NCT00673673?

The interventions under investigation include: FOLFOX (DRUG), bevacizumab (DRUG).

Who is sponsoring clinical trial NCT00673673?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00673673 being conducted?

This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00673673's enrollment target sits among peer trials

39 133rd of 153 higher than 20 of 153 other Gastric Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03465592 · 39 participants · Phase 1

    Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

  • NCT03961776 · 39 participants

    Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems

  • NCT04050280 · 39 participants · Phase 2

    CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

  • NCT04190862 · 39 participants · Phase 1

    E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00673673, the US trial registry maintained by the National Library of Medicine. NCT00673673 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.